Cardiol Therapeutics annual return on equity
2021
2022
2023
2024
2025
Cardiol Therapeutics Return on Equity (ROE) Growth & History (CRDL)
Cardiol Therapeutics's return on equity was −158.75% for fiscal 2025.
View full Cardiol Therapeutics company overviewCardiol Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −158.75% | −20.28 pp |
| 2024 | 2024-12-31 | −138.47% | −68.54 pp |
| 2023 | 2023-12-31 | −69.93% | −21.77 pp |
| 2022 | 2022-12-31 | −48.16% | +22.53 pp |
| 2021 | 2021-12-31 | −70.69% | — |
Cardiol Therapeutics quarterly return on equity
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −25.22% | +31.62 pp |
| Q1 2026 | 2026-03-31 | −51.42% | −12.25 pp |
| Q4 2025 | 2025-12-31 | −52.57% | — |
| Q3 2025 | 2025-09-30 | −93.26% | — |
| Q2 2025 | 2025-06-30 | −56.84% | — |
| Q1 2025 | 2025-03-31 | −39.17% | — |
Cardiol Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Cardiol Therapeutics's return on equity decreased from −70.69% to −158.75%, a change of −88.06 percentage points. The latest reported quarter, Q2 2026, shows −25.22%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cardiol Therapeutics source filings ↗